Multiple sclerosis

Dietary interventions for multiple sclerosis‐related outcomes

Abstract Background Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system. Although the exact pathogenesis remains unknown, the leading theory is that it results from immune system dysregulation. Approved disease‐modifying therapy appears to modulate the immune system to improve MS‐related outcomes. There is substantial interest in the ability of dietary interventions […]

Share

Interventions for preventing falls in people with multiple sclerosis

Abstract Background Multiple sclerosis (MS) is one of the most prevalent diseases of the central nervous system with recent prevalence estimates indicating that MS directly affects 2.3 million people worldwide. Fall rates of 56% have been reported among people with MS in a recent meta‐analysis. Clinical guidelines do not outline an evidence‐based approach to falls […]

Share

Palliative care interventions for people with multiple sclerosis

Abstract Background People with multiple sclerosis (MS) have complex symptoms and different types of needs. These demands include how to manage the burden of physical disability as well as how to organise daily life, restructure social roles in the family and at work, preserve personal identity and community roles, keep self‐sufficiency in personal care, and […]

Share

Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients

Abstract Background Multiple sclerosis (MS) is a leading cause of neurological disability in young adults. The most widely accepted hypothesis regarding its pathogenesis is that it is an immune‐mediated disease. It has been hypothesised that intraluminal defects, compression, or hypoplasia in the internal jugular or azygos veins may be important factors in the pathogenesis of […]

Share

Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews

Abstract Background Multiple sclerosis (MS) is a major cause of chronic, neurological disability, with a significant long‐term disability burden, often requiring comprehensive rehabilitation. Objectives To systematically evaluate evidence from published Cochrane Reviews of clinical trials to summarise the evidence regarding the effectiveness and safety of rehabilitation interventions for people with MS (pwMS), to improve patient […]

Share

Non-pharmacological interventions for chronic pain in multiple sclerosis

Abstract Background Chronic pain is common and significantly impacts on the lives of persons with multiple sclerosis (pwMS). Various types ofnon‐pharmacological interventions are widely used, both in hospital and ambulatory/mobility settings to improve pain control in pwMS, but the effectiveness and safety of many non‐pharmacologicalmodalities is still unknown. Objectives This review aimed to investigate the […]

Share

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies

Abstract Background Antiphospholipid syndrome (APS) is an autoimmune disease characterised by the presence ofantiphospholipid (aPL) antibodies that have prothrombotic activity. Antiphospholipidantibodies are associated with an increased risk of pregnancy complications (recurrent miscarriage, premature birth, intrauterine growth retardation) and thrombotic events (both arterial and venous). The most common thrombotic events include brain ischaemia (stroke or transient […]

Share

Trihexyphenidyl for dystonia in cerebral palsy

Abstract Background Cerebral palsy occurs in up to 2.1 of every 1000 live births and encompasses a range of motor problems and movement disorders. One commonly occurring movement disorder amongst those with cerebral palsy is dystonia: sustained or intermittent involuntary muscle spasms and contractions that cause twisting, repetitive movements and abnormal postures. The involuntary contractions […]

Share

Respiratory muscle training for multiple sclerosis

Abstract Background Multiple sclerosis (MS) is a chronic disease of the central nervous system, affecting approximately 2.5 million people worldwide. People with MS may experience limitations in muscular strength and endurance – including the respiratory muscles, affecting functional performance and exercise capacity. Respiratory muscle weakness can also lead to diminished performance on coughing, which may […]

Share

Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis

Abstract Background Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the treatment of relapsing-remitting multiple sclerosis (RRMS). Objectives To compare the efficacy, tolerability and safety of alemtuzumab […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share